Online inquiry

IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15422MR)

This product GTTS-WQ15422MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15422MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ781MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ15277MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ12699MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ1252MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ7677MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ4496MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ8175MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ8304MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HM-12525A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW